Gout Flare — ED Treatment

Key Points

• Always consider septic arthritis in an acutely hot swollen joint.
• Crystals in synovial fluid do not completely exclude concomitant infection.
• Serum uric acid can be normal during a gout flare and should not be used alone to confirm or exclude gout.
• NSAIDs, colchicine, and glucocorticoids are first-line flare treatments.
• Low-dose colchicine is preferred over historic high-dose regimens.
• Choose therapy based on kidney function, bleeding risk, diabetes, cardiovascular disease, and drug interactions.
• Continue established allopurinol or febuxostat during an acute flare.
• Long-term urate lowering uses a treat-to-target strategy, generally serum urate below 6 mg/dL.

Algorithm

1. Assess for septic arthritis red flags and determine whether arthrocentesis is needed.
2. If aspirating, send synovial cell count, Gram stain, culture, and crystal analysis.
3. Select NSAID, low-dose colchicine, or glucocorticoid based on comorbidities and contraindications.
4. Use ice, rest, and joint protection as adjuncts.
5. Continue established urate-lowering therapy.
6. If infection is suspected, do not inject intra-articular steroid and manage septic arthritis urgently.
7. Arrange follow-up for urate target, flare prophylaxis, renal function, and long-term prevention.

Clinical Synopsis & Reasoning

Gout results from monosodium urate crystal deposition and often presents as abrupt severe monoarthritis with warmth, swelling, erythema, and exquisite tenderness. The first metatarsophalangeal joint is classic, but ankles, knees, wrists, fingers, and bursae can be involved. Fever and leukocytosis can occur, so neither excludes gout nor proves infection.

The key ED diagnostic problem is septic arthritis. A prior history of crystal-proven gout makes a typical recurrent flare more likely, but infection can coexist with crystals. Arthrocentesis is particularly important for a first episode, an atypical joint, systemic illness, immunosuppression, prosthetic joint, marked fever, bacteremia risk, or any presentation in which septic arthritis is plausible. Synovial fluid should be sent for cell count, Gram stain, culture, and crystal analysis. Needle-shaped, negatively birefringent monosodium urate crystals support gout, but their presence does not cancel a concerning culture evaluation.

Serum uric acid is not a reliable acute diagnostic test. The level can be normal during a flare and can be elevated in people without gout. It is more useful for long-term treat-to-target therapy than for deciding whether an acutely swollen joint contains urate crystals. Ultrasound and dual-energy CT can identify urate deposition in selected cases but are not substitutes for aspiration when infection is a concern.

Comorbid kidney disease, cardiovascular disease, peptic ulcer disease, anticoagulation, diabetes, infection risk, and medication interactions determine which anti-inflammatory therapy is safest. Ask whether the patient is already taking allopurinol or febuxostat. Stopping urate-lowering therapy during a flare causes urate fluctuation and is generally counterproductive.

Treatment Strategy & Disposition

Treat early. The 2020 American College of Rheumatology guideline supports oral colchicine, an NSAID, or a glucocorticoid as first-line flare therapy, with the choice driven by comorbidities, prior response, access, and patient preference. For colchicine, low-dose therapy is preferred over older high-dose regimens because efficacy is similar with fewer adverse effects. A standard adult acute regimen is 1.2 mg orally at onset followed by 0.6 mg one hour later, with subsequent dosing individualized. Renal or hepatic impairment and strong CYP3A4 or P-glycoprotein inhibitors can create serious colchicine toxicity.

NSAIDs are effective when kidney function, gastrointestinal bleeding risk, anticoagulation status, and cardiovascular risk allow. Use a full anti-inflammatory dose for the shortest necessary course. Glucocorticoids can be given orally, intramuscularly, or by intra-articular injection after infection is reasonably excluded. Intra-articular steroid is useful for one or two accessible joints and limits systemic exposure.

Ice and rest can reduce pain as adjuncts. Opioids do not treat crystal inflammation and should not be routine primary therapy. If the patient is already taking urate-lowering therapy, continue it. If long-term urate lowering is indicated and reliable follow-up exists, ACR guidance conditionally supports starting therapy even during a flare rather than waiting for complete resolution, with appropriate anti-inflammatory prophylaxis.

Long-term allopurinol is first-line urate-lowering therapy for most patients who need it, including many with CKD, and is titrated to a serum urate target below 6 mg/dL. Starting dose should be low, especially in CKD. HLA-B*58:01 testing is recommended before allopurinol in higher-risk ancestry groups such as many Southeast Asian and African American patients. ED clinicians do not need to solve long-term titration during every flare, but they should avoid disrupting a sound chronic regimen.

Epidemiology / Risk Factors

• Gout is the most common inflammatory arthritis in many adult populations.
• Risk rises with CKD, diuretic use, metabolic syndrome, alcohol, high urate burden, and certain genetic factors.
• Flares commonly involve the first MTP joint but can occur in any peripheral joint.
• Hospitalization, surgery, dehydration, and abrupt urate shifts can trigger attacks.
• Untreated hyperuricemia can lead to tophi, chronic joint damage, and uric-acid nephrolithiasis.

Investigations

Medication Snapshot

Pharmacology

Prognosis / Complications

• An uncomplicated flare usually improves over days with prompt anti-inflammatory therapy.
• Repeated untreated flares can progress to chronic gouty arthritis and tophi.
• Effective treat-to-target urate lowering substantially reduces future flares over time.
• Patients with kidney or cardiovascular disease need a prevention strategy that considers comorbidity rather than relying on repeated NSAID courses.
• Septic arthritis mistaken for gout can rapidly destroy a joint and cause sepsis.

Patient Education / Counseling

• Start flare medication early at the first familiar signs when a clinician has provided a safe plan.
• Do not stop allopurinol or febuxostat simply because a flare started.
• Limit heavy alcohol use and address weight, blood pressure, diabetes, and kidney disease as part of gout care.
• Seek urgent reassessment for high fever, systemic illness, a first hot swollen joint, prosthetic-joint involvement, or failure to improve.
• Discuss long-term urate target and adherence rather than using diet alone as the main preventive strategy.
• Review drug interactions before taking colchicine, especially with new antibiotics or antifungals.

Notes

The safest gout diagnosis is a crystal diagnosis when the presentation is new or atypical. A red, exquisitely painful joint in a patient with prior gout can still be infected, particularly when the patient is immunocompromised or bacteremic. Crystals and bacteria are not mutually exclusive.

Long-term management has also changed from episodic flare treatment to urate control. Repeated emergency treatment without a serum urate target leaves the underlying crystal burden in place. Allopurinol adherence, dose titration, and prophylaxis during initiation matter more than avoiding a long list of foods.

References

1. American College of Rheumatology 2020 Guideline for the Management of Gout — Link